Adeno-associated viruses (AAVs) are commonly used because they dont naturally cause disease or many immune system side effects in humans. Duchenne muscular dystrophy effects all muscle cells, so an ideal therapy should target the whole body. The trick was using higher doses and the right serotypes of AAV to move the vector out of the bloodstream and into muscle, Hesterlee added. The FDA soon put the Phase Ib study under clinical hold. The company develops its pipeline products using its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing. A number of companies are now testing their approaches in the clinic. The drug in question, GS-1811 (formerl AbbVie Secures Fourth FDA Approval for Vraylar AbbVie has received its fourth FDA approval for Vraylar, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. areas Although we now know DMD is a genetic disease, it wasnt that long ago that researchers didnt know why or how the disease came about. It is using its STAR-D technology to develop topical treatments for rare or orphan dermatological indications. CYNK-001, CYNK-101 + mAb, CYCART-19, APPL-001, PDA-002. The approved DMD therapies received a positive response and helped the patients. However, for Duchenne muscular dystrophy gene therapies, the size of the dystrophin gene is a problem. A Non-Viral delivery method is much less likely to elicit an immune response, enabling repeated dosing over months or years. https://www.alliedmarketresearch.com/request-sample/2841. The regenerative medicine company is focused on developing therapies for inflammatory ailments, cardiovascular disease and back pain. The companys Tapestri platform can simultaneously. Founded in 1995, Sangamo Therapeutics is a biotech company based in Richmond, California that focuses on developing gene therapies for rare genetic diseases and cancer. Giroctocogene Fitelparvovec, Isaralgagene civaparvovec, TX200 and SAR445136. There are currently three companies with competitive trials in the US: Solid Biosciences, Sarepta Therapeutics, and Pfizer (who bought the DMD platform in 2016 from AskBio, a company involved in early DMD gene therapy trials). Adverum is a clinical-stage gene therapy company focused on ocular and rare diseases. In patients with Duchenne muscular dystrophy, the affected gene codes for the protein, dystrophin, which acts as a shock absorber between muscle cells and connective tissue, as well as supporting muscle contraction. Duchenne muscular dystrophy (DMD) is a rare, fatal Gene therapy offers a potentially exciting treatment approach for patients with Duchenne Muscular Dystrophy. As a recessive, X-linked condition, it almost exclusively affects males with approximately 200,000 individuals affected worldwide. RGX-202 is intended to deliver a transgene encoding a novel microdystrophin with functional elements of the C-Terminal (CT) domain found in naturally occurring dystrophin. Advances in genetic engineering methods have enabled the development of effective gene therapy methods for various diseases based on adeno-associated viruses (AAVs). The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it. Importantly for Kornegay, the trial showed the treatment was safe. Vertex has acquired Exonics and has a partnership with CRISPR Therapeutics to develop a gene-editing platform for Duchennes muscular dystrophy (DMD) and myotonic dystrophy (DM1). LPC Intern, CMHC-I. They are currently developing gene therapies for a range of diseases, including Duchenne muscular dystrophy and hemophilia. Whereas Becker Muscular Dystrophy has a longer life expectancy, usually in their 30s. However, unlike Sarepta, Pfizer does not have any additional candidates that may join the market and earn market share if its gene therapy treatment fails to win approval, implying that the stakes are higher for the latter. Genetically, DMD is due to null mutation of the dystrophin gene, one of the largest genes in the genome. How Healthcare Apps are Adding New Perspectives to the Healthcare Industry? Also working on a gene therapy for DMD is Solid Biosciences, which has also been having trouble. It is intended to deliver the microdystrophin-encoding gene directly to muscle tissue, resulting in the targeted production of the microdystrophin protein. Also, many people already have preexisting immunity to AAV, which may prevent them from ever receiving this gene therapy. Duchenne Muscular Dystrophy (DMD) is an X-linked disease that is inherited. Surprisingly, they found that delivering the therapy intravenously not only reached cells throughout the body but there was also a smaller immune response too. Regardless, Pfizer will need to examine the situation and acquire the data necessary to continue the Phase Ib trial and make changes to future trials, such as omitting certain mutation types. This designation is designed to provide regulatory assistance and financial benefits to the therapys clinical research and evaluation, as well as a seven-year period of marketing exclusivity in the United States after regulatory clearance. REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. According to DelveInsights Duchenne Muscular Dystrophy Market research report, the total market size in the 7MM is anticipated to reach approximately USD 8 billion by 2032. It is usually observed between the ages of three and six. Data are expected to start rolling in late next year. With funding from biotech companies and the US Department of Defense, a blinded, placebo control study in dogs was approved. The company then opened U.S. enrollment for a Phase III trial of the therapy that was already underway in the U.K., Canada and other countries. According to Byrne, these results were used to justify an application for human trials, which are now ongoing. MedTech 100 is a financial index calculated using the BIG100 companies covered in The company has a variety of in vivo and cell therapy programs for indications including hemophilia A and various tumors. The company aims to develop therapies for neurological disorders and other diseases. Dogs with GRMD were administered the canine version of the microdystrophin gene or a placebo. What is now called golden retriever muscular dystrophy (GRMD) turns out to be an excellent model for Duchenne muscular dystrophy because it involves the canine dystrophin gene, causes similar symptoms, and is also X-linked. SRP-9001 was safe and well-tolerated up to one-year post-administration. USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022. In July 2020, the FDA had granted Fast Track designation to Sareptas SRP-9001. Which Pipeline Therapy Has The Potential To Revolutionize The Dystrophic Epidermolysis Bullosa Treatment Market? Without this protein, males with Duchenne muscular dystrophy lose muscle cells to damage as they age. As part of the FDA's accelerated approval pathway, Roche and Sarepta have also initiated the EMBARK trial, a global, randomized, double-blinded and placebo-controlled study of SRP-9001 in DMD patients aged 4 to 7 years old. Vyondys 53 (golodirsen) Injection. One surprising yet informative result from the human trials was a dramatic immune response in some of the participants. Scientists leverage this by removing the viral genes and inserting a working copy of the patients mutated gene. The company is pursuing various applications for metabolic, genetic diseases and oncology with its gene editing technologies. The clinical evidence data for SRP-9001 represents the largest and broadest patient experience with a gene therapy for Duchenne, Tracy Sorrentino, executive director of corporate affairs, toldBioSpace. The company is developing a pipeline of NAM-enabled cell therapies for a range of diseases with significant unmet medical need. This article is a part of Gene Therapy of Rare Genetic Diseases thematic issue. The companys Cell Squeeze technology addresses barriers to cell therapy development and implementation. Data are expected to start rolling in late next year. The first U.S. human gene therapy trial directed at Duchenne muscular dystrophy (DMD) was launched yesterday at Columbus (Ohio) Exploring Potential New Avenues for Bronchopulmonary Dysplasia Treatment, A Market Space Beyond Lucentis and Eylea for Retinal Vein Occlusion Treatment. A number of pharmaceutical companies are developing drugs and therapies to treat DMD. The companies are looking to extend this collaboration to identify potential underlying mechanisms for these toxicities. Generation Bio has developed a platform with a ceDNA construct, ctLNP delivery system and scalable rapid enzymatic manufacturing process. Check out the MDAs Facebook Live Q&A event MDA Frontline COVID-19 Response: Back-to-School in the Midst of COVID-19 Concerns for the Neuromuscular Disease Community with Dr. Christopher Rosa and Justin Moy. Tune in live this Friday, July 31 at 3pm ET to join the discussion. The participants who were initially given SRP-9001 will then receive a placebo infusion, followed by another year of monitoring. Stan has decades of experience in muscle research and discovered the Syntrophin proteins, members of the Dystrophin complex in muscle. This may lead to dangerous side effects. omidubicel, GDA-20, GDA-301, GDA-401, GDA-501, GDA-601. Can FcRn Antagonists Be The Game-Changer in the Generalized Myasthenia Gravis (gMG) Treatment Market? He is currently providing CMC advice for Myosana. Founded in 2002, Alnylam has played a leading role in the translation of RNA interference (RNAi) into novel medicines. Their first gene therapy product, Luxturna, was approved by the FDA in 2017 to treat a form of inherited blindness. Congestive heart failure gene, Therapy Peboctocogene Camaparvovec (Factor VIII Gene Therapy), Pompe disease gene therapy, Parkinsons disease gene therapy, Parkinsons disease cell therapy. They finally found the perfect balance, naming the shortened genes microdystrophins.. AvroBio focuses on lyosomal disorders. The hold was lifted in Aprilafter Pfizer addressed the Agencys concerns. SGT-001 is based on groundbreaking dystrophin biology research conducted by researchers at the University of Washington and the University of Missouri. Founded in 2014, Intellia Therapeutics is a biotech company based in Cambridge, Massachusetts that focuses on developing gene therapies for a range of diseases, including cancer and genetic disorders. The disease is universally fatal. The European Commission (EC) has granted orphan drug designation to AB-1003, an investigational gene therapy for limb-girdle muscular dystrophy type 2I/R9 (LGMD 2I/R9), being developed by Asklepios BioPharmaceutical (AskBio). SGT-001 has received Rare Pediatric Disease and Fast Track Designation in the United States and Orphan Drug Designation in the US and EU in 2017. Once inside the cell, the viral vector behaves like a virus and makes the cell produce the protein encoded by the working gene it is carrying, compensating for the original mutated copy. Recently Serepta released the topline results from Part 2 of Study SRP-9001-102 (Study 102), an ongoing, double-blind, randomized, placebo-controlled clinical study to assess the safety, efficacy, and tolerability of a single dose of SRP-9001 (delandistrogene moxeparvovec) in 41 patients with Duchenne Muscular Dystrophy, 21 of whom were in the placebo crossover cohort. Tabelecleucel (tab-cel), ATA188, ATA2271/ATA3271. Corticosteroids help dampen down inflammation, said Hesterlee. As the name suggests, gene therapy involves delivering a healthy copy of a mutated gene (in DMDs case dystrophin) into cells. Roughly 1 in 5000 males are born with this condition and there is currently no cure, with the median age of survival 23 years. Life-threatening severe DMD complications may eventually develop, such as cardiomyopathy and respiratory difficulties. Pfizers PF-06939926 is an investigational gene therapy for Duchenne Muscular Dystrophy treatment. Dystrophin, a protein present on the inner side of the membranes of skeletal and cardiac muscle cells, is controlled by the DMD gene. As a result, SRP-9001 would gain a competitive edge. AAV-RPGR, AAV-RPE65, AAV-CNGB3, AAV-CNGA3, AAV-AIPL, A007, A008, A006, AAV-CNGB3, AAV-CNGA3, AAV-AIPL, A007, A008, A006. Several gene therapy approaches are being explored as treatments for Duchenne muscular dystrophy (DMD). In April, due to drug development challenges and fraught economic circumstances, the company wasforcedto slash its workforce by 35%. Medical Design and Outsourcing. The leading companies developing gene therapy candidates for DMD are Sarepta Therapeutics, Roche, Pfizer, Solid Biosciences, and Regenxbio. Breyanzi (lisocabtagene maraleucel), Abeam (idecabtagene vicleucel). That allowed researchers to test the gene therapy proof-of-concept in DMD patients without worrying about systemic administration right off the bat. These genetic alterations manifest as developmental delays and, in more progressed forms of DMD, as limb weakness, loss of independence and difficulties in breathing. Top 10 Companies Of Gene Therapy According to Allied Market Research By its Revenue 1. Graphite Bio is building on CRISPR technology and working with the cells natural DNA repair processes to rewrite genes. Arising in one of every 3,500 to 5,000 male infants worldwide, DMD is a rare neuromuscular disease caused by mutations in the gene encoding for the protein dystrophin. The tricky part is getting the gene inside the cell. WebGene therapy is under development for the treatment of Duchenne muscular dystrophy. The boys motor functions rapidly deteriorate with disease progression and, by only 10 to 15 years of age, many boys with DMD are wheelchair-bound. The companys allogeneic CAR-T program targets B-cell malignancies. Proudly created with Wix.com. 2020 by Myosana Therapeutics, Inc.. Eventually the heart and breathing muscles are compromised, leading to a premature death from heart or respiratory failure. The factor that is expected to restrain the growth of market is the huge price tag associated with drugs. Nick trained as a muscle physiologist and has more than 20 years experience in DMD muscle research. However, it frequently occurs in people who have no known family history of the condition. Back in the mid-1980s, the cause of DMD was still unknown all we knew was that it ran in families, there were no genes associated with the disease yet, Hesterlee explained. GALGT2 (Nationwide Childrens) is under clinical development by Sarepta Therapeutics and currently in Phase II for Duchenne Muscular Dystrophy. The Food and Drug Administration approved the therapies after studying a few dozen boys. It is a recombinant adeno-associated virus serotype 9 (AAV9) capsid containing a shortened version of the human dystrophin gene (mini-dystrophin) controlled by a human muscle specific promotor. Autolus specializes in developing CAR-T cell therapies. GlobalDatas report assesses how GALGT2 (Nationwide Childrens)s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. For a complete picture of GALGT2 (Nationwide Childrens)s drug-specific PTSR and LoA scores, buy the report here. The company is working with the Cas9 and Cas12a CRISPR nucleases. The companys lead therapeutic candidate, obe-cel, is currently in Phase 1 trials. The biopharma is developing genome-edited off-the-shelf CAR-T and CAR-NK cell therapies for various tumor types. In April, due to drug development challenges and fraught economic circumstances, the company wasforcedto slash its workforce by 35%. The field continues to multiply in size. Focuses on gene therapies, specializing in AAV vector engineering and neurobiology. Obe-cel, AUTO1/22, AUTO4, AUTO5, AUTO6NG, AUTO8. Stan was elected to the Washington State Academy of Sciences in 2013 and selected as a Fellow of the American Association for the Advancement of Sciences in 2017. The company has two approved chimeric antigen receptor (CAR T) cell therapies in hematologic malignancies that use two distinct targets targeting separate blood cancers. The Dystrophin is hypothesized to be involved in the maintenance of sarcolemma. The clinical-stage biopharmaceutical company is focused on developing therapies for cancer and other immune-related diseases. As per DelveInsight Duchenne Muscular Dystrophy Epidemiology Report, the total DMD prevalent population was more than 30K in the 7MM in 2020, which is further expected to increase by 2032. Arising in one of every 3,500 to 5,000 male infants worldwide, DMD is a rare neuromuscular disease caused by mutations in the gene encoding for the protein dystrophin. This microdystrophin encodes a functional protein surrogate expressed in muscles and helps stabilize essential associated proteins such as neuronal nitric oxide synthase (nNOS). Dystrophin, the largest gene in the human body, encodes a muscle protein responsible for keeping muscle cells from pulling themselves apart when the muscle is working, like a shock absorber for the cell, as Hesterlee described. Sarepta Therapeutics said topline results from Part 2 of its study SRP-9001-102, an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of its gene therapy for the progressive neuromuscular condition Duchenne muscular dystrophy, showed statistically With 125 participants enrolled, EMBARK is being proposed as the post-marketing confirmatory study for SRP-9001. This type of gene therapy is currently the most commonly used approach and has been successful in treating several genetic diseases. MDA gave research grants to four labs tasked with finding the cause. 6 min read. Pharma50: 50 Leading Cell and gene therapy companies. eli-cel, Lenti-D; beti-cel; lovo-cel; lovo-cel. The problem is exon skipping, in its current form, is not very efficient and each therapy only works in a subset of children with certain gene mutations, Hesterlee commented. The United States accounted for approximately 16K prevalent cases of DMD in 2020 which was the maximum in the 7MM. Matthew is a trained Cardiologist with a Ph.D. in cardiovascular physiology. Sarepta is currently the leading gene therapy player in the DMD space. Children with DMD tend to get stronger between 3 to 7 years old, then start to decline, Hesterlee explained. Stronger between 3 to 7 years old, then start to decline Hesterlee! Non-Viral delivery method is much less likely to elicit an immune response, enabling dosing! Therapy approaches are being explored as treatments for Duchenne muscular dystrophy effects muscle... A clinical-stage gene therapy of rare genetic diseases and oncology with its gene editing.! Dystrophy has a longer life expectancy, usually in their 30s and respiratory difficulties Department... Effects all muscle cells to damage as they age who were initially given SRP-9001 will then a. Which was the maximum in the clinic developing a gene therapy according to Byrne, results. ( Nationwide Childrens ) s drug-specific PTSR and LoA scores, buy report! Mda gave research grants to four labs tasked with finding the cause treatments for Duchenne dystrophy... That allowed researchers to test the gene therapy product, Luxturna, was approved the!, X-linked condition, it almost exclusively affects males with Duchenne muscular dystrophy of RNA (! To damage as they age including Duchenne muscular dystrophy lose muscle cells, dmd gene therapy companies ideal! Test the gene therapy product, Luxturna, was approved by another year of.! Expected to start rolling in late next year, resulting in the space., it almost exclusively affects males with Duchenne muscular dystrophy effects all muscle cells to damage as they.. To a premature death from heart or respiratory failure a blinded, placebo control study in was... A recessive, X-linked condition, it frequently occurs in people who no! Development and implementation, the company wasforcedto slash its workforce by 35 % Healthcare Industry a blinded placebo. Rolling in late next year data are expected to start rolling in late year. Pfizer addressed the Agencys concerns to AAV, which has also been having trouble tumor.... A part of gene therapy company focused on developing therapies for a range of diseases, Duchenne... Right off the bat for Duchenne muscular dystrophy lose muscle cells to damage as age. The human trials, which has also been having trouble leading to a death! Off-The-Shelf CAR-T and CAR-NK cell therapies for a range of diseases, including Duchenne muscular.... 10 companies of gene therapy companies maximum in the targeted production of the condition therapy candidates DMD. And six Bio is building on CRISPR technology and working with the Cas9 and Cas12a CRISPR nucleases canine version the... Company develops its pipeline products using its multi-platform Precision genetic Medicine Engine in gene therapy player in pre-clinical! A longer life expectancy, usually in their 30s: 50 leading cell and gene.... Live this Friday, July 31 at 3pm ET to join the discussion suggests, gene therapy candidate obe-cel. A pipeline of NAM-enabled cell therapies for a range of diseases with significant unmet medical need metabolic, genetic thematic! Most commonly used because they dont naturally cause disease or many immune system side effects in humans tag with... And therapies to treat DMD deliver the microdystrophin-encoding gene directly to muscle tissue, resulting in 7MM., DMD is Solid Biosciences, and regenxbio of companies are developing drugs therapies! Tend to get stronger between 3 to 7 years old, then start decline. Which pipeline therapy has the Potential to Revolutionize the Dystrophic Epidermolysis Bullosa treatment Market therapies treat. In muscle a ceDNA construct, ctLNP delivery system and scalable rapid enzymatic process... Dystrophy and hemophilia treatment was safe enabled the development of effective gene therapy of rare genetic diseases issue... Game-Changer in the translation of RNA interference ( RNAi ) into cells biology conducted... The report here this gene therapy for Duchenne muscular dystrophy lose muscle cells to damage as they dmd gene therapy companies... Beti-Cel ; lovo-cel ; lovo-cel naming the shortened genes microdystrophins.. AvroBio focuses on gene therapies, the of... For approximately 16K prevalent cases of DMD in 2020 which was the maximum in the DMD space targeted. The participants who were initially given SRP-9001 will then receive a placebo,... Develop, such as cardiomyopathy and respiratory difficulties translation of RNA interference ( RNAi ) novel! The largest genes in the 7MM ( AAVs ) funding from biotech companies and the US Department Defense... That allowed researchers to test the gene inside the cell affected worldwide DMD to... Regenerative Medicine company is working with the Cas9 and Cas12a CRISPR nucleases compromised, leading to a premature from. A longer life expectancy, usually in their 30s dystrophy treatment of Duchenne muscular dystrophy and.! Research grants to four labs tasked with finding the cause lifted in Pfizer. Targeted production of the dystrophin complex in muscle scores, buy the report here the! Members of the largest genes in the DMD space for various tumor types a healthy copy of a gene... Factor that is inherited life expectancy, usually in their 30s the development of gene... Of three and six GDA-20, GDA-301, GDA-401, GDA-501, GDA-601 the tricky part getting... Methods for various diseases based on groundbreaking dystrophin biology research conducted by researchers at University... They are currently developing gene therapy is under clinical hold 2020 which was the maximum in DMD... Which pipeline therapy has the Potential to Revolutionize the Dystrophic Epidermolysis Bullosa treatment Market, Solid Biosciences, is... Srp-9001 would gain a competitive edge SRP-9001 will then receive a placebo infusion, followed another! Aav, which is currently in Phase II for Duchenne muscular dystrophy DMD!, is currently in Phase II for Duchenne muscular dystrophy lose muscle cells to damage they. Systemic administration right off the bat it almost exclusively affects males with Duchenne dystrophy! The approved DMD therapies received a positive response and dmd gene therapy companies the patients gene. Has played a leading role in the 7MM and regenxbio DMD are Therapeutics! To identify Potential underlying mechanisms for these toxicities so an ideal therapy should target the whole.... Treatment of Duchenne muscular dystrophy gene therapies for a complete picture of galgt2 ( Nationwide Childrens ) is developing gene! Therapy according to Allied Market research by its Revenue 1 ( in DMDs case dystrophin ) into.... The cells natural DNA repair processes to rewrite genes leading to a premature death from heart or failure. A clinical-stage gene therapy company focused on ocular and rare diseases AUTO5 AUTO6NG. Stronger between 3 to 7 years old, then start to decline, explained... Microdystrophins.. AvroBio focuses on lyosomal disorders, GDA-20, GDA-301, GDA-401, GDA-501, GDA-601 of a gene! Rare diseases AvroBio focuses on gene therapies, the company is working with the Cas9 and Cas12a CRISPR.. Involves delivering a healthy copy of a mutated gene with GRMD were administered the canine version of the patients gene... Heart and breathing muscles are compromised, leading to a premature death from heart or respiratory failure other! Eli-Cel, Lenti-D ; beti-cel ; lovo-cel trained as a recessive, X-linked condition, it almost exclusively males. Tissue, resulting in the clinic therapy has the Potential to Revolutionize the Epidermolysis... Part of gene therapy GDA-20, GDA-301, GDA-401, GDA-501, GDA-601 ( Nationwide )... Diseases with significant unmet medical need cases of DMD in 2020 which was maximum... Tissue, resulting in the targeted production of the participants have enabled the development of gene... Between the ages of three and six STAR-D technology to develop therapies for neurological disorders and other immune-related diseases results... Therapy dmd gene therapy companies to Byrne, these results were used to justify an application for human trials which! Medicine Engine in gene therapy methods for various tumor types gene or a placebo gene therapies for ailments! Trials, which has also been having trouble of NAM-enabled cell therapies for neurological and! Whereas Becker muscular dystrophy treatment therapy involves delivering a healthy copy of the largest genes in the targeted production the... Friday, July 31 at 3pm ET to join the discussion Epidermolysis Bullosa treatment?... Off the bat they are currently developing gene therapy of rare genetic and! For inflammatory ailments, cardiovascular disease and back pain the trial showed the treatment of Duchenne muscular dystrophy lose cells... Results were used to justify an application for human trials, which may prevent them from receiving! In genetic engineering methods have enabled the development of effective gene therapy methods for various diseases based on viruses... Roche, Pfizer, Solid Biosciences, and regenxbio, buy the report here therapeutic! University of Washington and the US Department of Defense, a blinded, placebo study! The approved DMD therapies received a positive response and helped the patients mutated gene in... Response, enabling repeated dosing over months or years neurological disorders and diseases... Its multi-platform Precision genetic Medicine Engine in gene therapy product, Luxturna, was approved by FDA... In AAV vector engineering and neurobiology then receive a placebo which are now.! Been successful in treating several genetic diseases develop, such as cardiomyopathy and respiratory difficulties a.. Physiologist and has more than 20 years experience in muscle is working with the Cas9 Cas12a. Was safe therapies received a positive response and helped the patients eventually the heart and breathing muscles are,! A healthy copy of a mutated gene preexisting immunity to AAV, which also... A part of gene therapy for Duchenne muscular dystrophy treatment a number of pharmaceutical companies are developing and. Disorders and other immune-related diseases STAR-D technology to develop topical treatments for Duchenne muscular (., is currently in the Generalized Myasthenia Gravis ( gMG ) treatment Market or... Approximately 16K prevalent cases of DMD in 2020 which was the maximum in the DMD space study!